Long-acting insulin does not increase the risk of acute myocardial infarction – or heart attack – in people with type 2 diabetes, according to new research.
The study, conducted by researchers from the Leibniz Institute for Prevention Research and Epidemiology in Bremen, Germany, compared the impact of long-acting insulin analogs with other basal insulin therapies on the risk of heart attack in people with type 2 diabetes. No significant differences were observed. A previous study, however, suggested that long-acting insulin increased heart attack risk.
The researchers examined data from 21,501 type 2 diabetes patients who had recently begun to take insulin; some were treated with premixed insulin, some with analog insulin, and some with human neutral protamine Hagedorn (NPH) insulin.
The researchers observed no significant increase in heart attack risk from the use of either type of insulin.
“In contrast to a former database study, no difference was observed for the risk of AMI between long-acting analog and NPH insulin in this study,” the researchers wrote.
“Neither long-acting insulin nor premix insulin appears to be associated with acute MI in patients with type 2 diabetes.”
The findings were published in Diabetes, Obesity and Metabolism.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…